{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Rofecoxib",
  "nciThesaurus": {
    "casRegistry": "162011-90-7",
    "chebiId": "CHEBI:8887",
    "chemicalFormula": "C17H14O4S",
    "definition": "A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties.  Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins.  COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2.",
    "fdaUniiCode": "0QTW8Z7MCR",
    "identifier": "C1832",
    "preferredName": "Rofecoxib",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C80509"
    ],
    "synonyms": [
      "4-[4'-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone",
      "MK 966",
      "ROFECOXIB",
      "Rofecoxib",
      "Vioxx",
      "rofecoxib"
    ]
  }
}